NCT03863574View on ClinicalTrials.gov

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

March 20, 2020

Study Completion Date

March 20, 2020

Conditions
Non Alcoholic Steatohepatitis
Interventions
DRUG

Saroglitazar Magnesium 2mg

Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.

DRUG

Saroglitazar Magnesium 4mg

Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.

DRUG

Placebos

Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.

Trial Locations (6)

23298

Virginia Commonwealth University, Richmond

37076

Digestive Health Research, Hermitage

38138

Gastro One, Germantown

39216

Southern Therapy and Advanced Research (STAR) LLC, Jackson

78215

Texas Liver Institute, San Antonio

78229

Clinical Trials of Texas, Inc., San Antonio

All Listed Sponsors
lead

Zydus Therapeutics Inc.

INDUSTRY

NCT03863574 - Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis | Biotech Hunter | Biotech Hunter